Literature DB >> 24403021

LncRNAs: new players in gliomas, with special emphasis on the interaction of lncRNAs With EZH2.

Er-Bao Bian1, Jia Li, Yong-Sheng Xie, Gang Zong, Jun Li, Bing Zhao.   

Abstract

Gliomas are the most common primary malignancy in the brain, accounting for 50-60%. Despite all the efforts of cytoreductive surgery in combination with intense chemoradiotherapy, glioma remains an incurable disease. Recent studies have shown that long noncoding RNAs (lncRNAs) are involved in the pathology of gliomas. LncRNAs are involved in many cellular processes, such as angiogenesis, invasion, cell proliferation, and apoptosis. In this review we focus on the dysregulation of lncRNAs in gliomas. We also address that epigenetic modification such as DNA methylation and microRNAs interact with lncRNAs in gliomas. In addition, the interaction of lncRNAs with signaling pathways in gliomas is discussed systematically, with particular emphasis on the interaction of lncRNAs with EZH2. Such approaches provide valuable insights into the potential future applications of lncRNAs in the treatment of gliomas.
© 2014 Wiley Periodicals, Inc., A Wiley Company.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24403021     DOI: 10.1002/jcp.24549

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  25 in total

1.  An immune-related lncRNA signature for patients with anaplastic gliomas.

Authors:  Wen Wang; Zheng Zhao; Fan Yang; Haoyuan Wang; Fan Wu; Tingyu Liang; Xiaoyan Yan; Jiye Li; Qing Lan; Jiangfei Wang; Jizong Zhao
Journal:  J Neurooncol       Date:  2017-11-23       Impact factor: 4.130

2.  Long noncoding RNA LINC00152 is a potential prognostic biomarker in patients with high-grade glioma.

Authors:  Wen Wang; Fan Wu; Zheng Zhao; Kuan-Yu Wang; Ruo-Yu Huang; Hao-Yuan Wang; Qing Lan; Jiang-Fei Wang; Ji-Zong Zhao
Journal:  CNS Neurosci Ther       Date:  2018-03-25       Impact factor: 5.243

3.  Tudor-staphylococcal nuclease regulates the expression and biological function of alkylglycerone phosphate synthase via nuclear factor-κB and microRNA-127 in human glioma U87MG cells.

Authors:  Yongqiang Zhang; Jun Jia; Ying Li; Yan-Ge Chen; Huan Huang; Yang Qiao; Yu Zhu
Journal:  Oncol Lett       Date:  2018-04-13       Impact factor: 2.967

4.  Differential lncRNA expression profiles in recurrent gliomas compared with primary gliomas identified by microarray analysis.

Authors:  Yi Chen; Jian-Jin Wu; Xian-Bin Lin; Yi Bao; Zhen-Hua Chen; Cheng-Ran Zhang; Zheng Cai; Jue-Yu Zhou; Mao-Hua Ding; Xiao-Jun Wu; Wei Sun; Jun Qian; Lei Zhang; Lei Jiang; Guo-Han Hu
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 5.  Prognostic and clinicopathological significance of long non-coding RNA in glioma.

Authors:  Junhong Li; Ruofei Liang; Chen Song; Yufan Xiang; Yanhui Liu
Journal:  Neurosurg Rev       Date:  2018-03-21       Impact factor: 3.042

6.  The Potential Roles of Long Noncoding RNAs (lncRNA) in Glioblastoma Development.

Authors:  Shuang Liu; Ramkrishna Mitra; Ming-Ming Zhao; Wenhong Fan; Christine M Eischen; Feng Yin; Zhongming Zhao
Journal:  Mol Cancer Ther       Date:  2016-10-26       Impact factor: 6.261

7.  Expression of LOC285758, a Potential Long Non-coding Biomarker, is Methylation-dependent and Correlates with Glioma Malignancy Grade.

Authors:  Alenka Matjasic; Mara Popovic; Bostjan Matos; Damjan Glavac
Journal:  Radiol Oncol       Date:  2017-01-14       Impact factor: 2.991

Review 8.  Long non-coding RNA in glioma: signaling pathways.

Authors:  Jia Shi; Bo Dong; Jiachao Cao; Yumin Mao; Wei Guan; Ya Peng; Suinuan Wang
Journal:  Oncotarget       Date:  2017-04-18

Review 9.  The Roles Played by Long Non-Coding RNAs in Glioma Resistance.

Authors:  Yeonsoo Chae; Jungwook Roh; Wanyeon Kim
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

Review 10.  Long Non-Coding RNAs: The Key Players in Glioma Pathogenesis.

Authors:  Karrie Mei-Yee Kiang; Xiao-Qin Zhang; Gilberto Ka-Kit Leung
Journal:  Cancers (Basel)       Date:  2015-07-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.